Ireland - English - HPRA (Health Products Regulatory Authority)

3m health care limited - pirbuterol hydrochloride - tablets - 15 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

3m health care limited - pirbuterol -

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 1.25 mg in 0.5 ml - levalbuterol inhalation solution (concentrate) is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6)] . there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medication, including levalbuterol inhalation solution during pregnancy. to enroll in mothertobaby pregnancy studies’ asthma & pregnancy study or for more information about the registry, call 1-877- 311-8972 or visit www.mothertobaby.org/ongoing-study/asthma. there are no adequate and well-controlled studies of levalbuterol inhalation solution (concentrate) in pregnant women. there are clinical considerations with the use of le

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 0.31 mg in 3 ml - levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. risk summary there are no adequate and well-controlled studies of levalbuterol inhalation solution in pregnant women. there are clinical considerations with the use of levalbuterol inhalation solution in pregnant women [see clinical considerations]. following oral administration of levelbuterol hcl to pregnant rabbits, there was no evidence of teratogenicity at doses up to 25 mg/kg/day [approximately 108 times the maximum recommended human daily inhalation dose (mrhdid) of levalbuterol hcl for adults on a mg/m2 basis]; however, racemic a

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 1.25 mg in 0.5 ml - levalbuterol inhalation solution (concentrate) is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. risk summary there are no adequate and well-controlled studies of levalbuterol inhalation solution concentrate in pregnant women. there are clinical considerations with the use of levalbuterol inhalation solution concentrate in pregnant women [see clinical considerations]. following oral administration of levalbuterol hcl to pregnant rabbits, there was no evidence of teratogenicity at doses up to 25 mg/kg/day [approximately 108 times the maximum recommended human daily inhalation dose (mrhdid) of levalbuterol hcl for adults

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2 mg - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 4 mg - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 0.63 mg in 3 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components. read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication, as you may want to read them again. albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about albuterol sulfate inhalation solution and the condition for which it has been prescribed. contact them if you have additional questions. storing your medicine store albuterol sulfate inhalation solution between 20° and 25° c (68° and 77° f). [see usp controlled room temperature]. vials should be protected from light before use, therefore, keep unused vials in the foil pouch. d

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 0.75 mg in 3 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

nephron pharmaceuticals corporation - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 1.25 mg in 3 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components.